Clinical Trial Update: Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes [Phase 1]

View source ↗

Summary

Phase 1 study of azacitidine plus bortezomib in relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes has completed enrollment and will ass…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Myelodoproliferative Neoplasms
• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Bortezomib (bortezomib)

Snippet

Sponsor: Ohio State University Comprehensive Cancer Center | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 1 | Status: COMPLETED